INOVIQ (ASX:IIQ) has completed disease specificity testing for its blood test designed to detect breast cancer, according to a Friday filing with the Australian bourse.

The test, which combines a monoclonal antibody with INOVIQ's SubB2M detection reagent, is proven to accurately identify CA15-3, a marker produced by cancer cells, improving the precision of cancer detection while minimizing false positives, the filing added.

The test showed 81% sensitivity and 93% specificity to detect breast cancer across all stages and is now effective for breast cancer monitoring, the filing said.

The test also effectively detected breast cancer with CA15-3 levels five times higher in patients than in healthy individuals, while returning negative results for 97.4% of non-cancer diseases.

Independent testing confirmed the INOVIQ test's superior specificity compared to an FDA-approved CA15-3 test, the filing added.

The company's next steps are to publish a scientific paper on the test to support partnerships, transfer the test to a high-throughput platform, conduct an in-clinic monitoring study, and secure a US laboratory partner for commercialization as a Laboratory Developed Test.

INOVIQ's shares rose 8% in recent Friday trade.